Get the latest tech news
With 23andMe in crisis, strengthening DNA security has never been more urgent
With all seven independent directors resigning from 23andMe millions of customers are questioning how the company plans to protect their DNA.
The Wall Street Journal recently wrote, “23andMe has never made a profit and is burning cash so quickly it could run out next year.” 23andMe also announced a telehealth platform, Lemonaid, selling weekly injections of compounded semaglutide, the active ingredient in Wegovy and Ozempic, through a new subscription product in an attempt to capitalize on the popularity of GLP-1 medications for weight loss, according to the WSJ. “This is a fairly unique situation (all of the independent directors resigned), but it’s emblematic of other issues in governance, trust, security and the damage to the company when external and internal folks lose confidence,” Baer told VentureBeat. And they are paying a settlement that responds to a suit specifically related to their failure to exercise enough security protection for the targeted attack against customers with Chinese or Ashkenazi Jewish ancestry,” Baer told VentureBeat.
Or read this on Venture Beat
